Noam Karni

TL;DR: The results show that COVID-19-associated chemosensory impairment is not limited to smell, but also affects taste and chemesthesis, and suggest that SARS-CoV-2 infection may disrupt sensory-neural mechanisms.

TL;DR: In this paper, the authors characterize longitudinal symptoms of mild coronavirus disease 2019 (COVID-19) patients for a period of 6 months, to potentially aid in disease management.

TL;DR: Self-reported quantitative olfactory changes, either alone or combined with other symptoms, provide a specific and powerful tool for clinical diagnosis of COVID-19.

TL;DR: A case-control study of patients who were polymerase chain reaction-tested for COVID-19 (112 positive and 112 negative participants), recruited during the first wave (March 2020-May 2020) of the COVID19 pandemic in Israel as mentioned in this paper, found that the ability to smell was decreased by 0 5 ± 1 5 in negatives and by 4 5 ± 3 6 in positives.

TL;DR: Each symptom can occur as first or later, though some are more likely to appear as firsts, and typically more than one symptom occurs at disease onset, and the severity of olfactory change is associated with its recovery time.